FDA Drug Approval Process In order for a pharmaceutical company to obtain FDA approval for a new drug, a long sequence of detailed testing and clinical trials must be administered. The approximate cost of putting a new drug through the approval is $500 million, and it takes an average of fifteen years for a drug to make it from initial testing to being available for patients. Furthermore, of every 5000 compounds that go through pre-clinical testing, only five advance to the human testing phase, and only one of these compounds will actually be approved. There are six key phases of testing that potential drugs go through on the path to FDA approval. These phases are early research / pre-clinical testing, clinical trials (phase I, phase II and phase III), FDA approval, and post-marketing testing.

The first phase of the drug approval process is pre-clinical testing. This consists of laboratory and animal testing to demonstrate biological activity of the new drug against...

The safety of the new drug is also assessed in the pre-clinical phase. This initial phase generally takes about 6.5 years to complete
After completion of the pre-clinical phase, the drug company files an Investigational New Drug Application (IND) with the FDA in order to begin testing the drug on humans. The IND outlines information known so far about the new compound and how new studies will be conducted. The Institutional Review Board where the studies will take place must review and approve the IND, and annual progress reports must be sent to the FDA.

The next phase is clinical trials. Volunteers in all three phases of the clinical trials must give informed consent before participation. Participants must know that the drug is investigational, understand risks involved, know their right to decline participation, and understand the pay incentive involved. In phase I, 20 to 80 healthy volunteers are used to test the drug over a 1.5-year…